Chief Laboratory Director Lab for Molecular Medicine, Mass General Brigham Personalized Medicine Cambridge, Massachusetts, United States
Session Description: Newborn genome sequencing has the potential to evaluate risk for treatable disorders currently undetected by conventional newborn screening. In this breakout session, three experts in the field of genomic sequencing and newborn screening will discuss the use of whole genome sequencing in improving the health outcomes of newborns. Attendees will gain a comprehensive understanding of the potential benefits and challenges of using whole genome sequencing as a screening tool for newborns, and the ethical, communication, data management, and social implications of genomic screening programs.
Learning Objectives:
Upon completion, participants will be able to discuss the potential benefits of using whole genome sequencing as a screening tool for newborns, and the importance of identifying treatable conditions early in life.
Upon completion, participants will be able to review the challenges of implementing genomic sequencing at scale for newborn screening.
Upon completion, participants will be able to consider the ethical, communication, data management, and social implications of genomic screening programs.
